TABLE 5.
Treatment-related adverse events in patients with CAP
| Eventa | No. (%) of patients
|
|||
|---|---|---|---|---|
| Comparative trial
|
Noncomparative trial, azithromycin (n = 212) | All azithromycin (n = 414) | ||
| Azithromycin (n = 202) | Cefuroxime ± erythromycin (n = 201) | |||
| Gastrointestinal | ||||
| Diarrhea | 11 (5.4) | 16 (8.0) | 7 (3.3) | 18 (4.3) |
| Nausea | 4 (2.0)b | 16 (8.0) | 12 (5.7) | 16 (3.9) |
| Abdominal pain | 2 (1.0) | 2 (1.0) | 9 (4.2) | 11 (2.7) |
| Vomiting | 0 (0.0) | 4 (2.0) | 6 (2.8) | 6 (1.4) |
| Insertion site | ||||
| Pain | 11 (5.4) | 12 (6.0) | 16 (7.5) | 27 (6.5) |
| Infection or inflammation | 7 (3.5) | 14 (7.0) | 6 (2.8) | 13 (3.1) |
a
Incidence of >2% in any group.
b
Significant difference between azithromycin and comparator group (P = 0.006).